CPS Capital, a leading Toronto-based private equity firm, is pleased to announce that it has made a strategic growth investment in PharmaSmart International alongside the existing management team.
PharmaSmart is a North American leader in the manufacture of technology enabled health kiosks and related patient engagement and connected health solutions. The company collects and manages validated patient data such as blood pressure, weight, BMI and blood glucose, and provides value-added health IT services to retail pharmacies, employers, providers and insurers. The proceeds from the investment provides growth capital for new customer contracts which will accelerate PharmaSmart’s connected health growth strategy across Canada and the United States.
Recommended AI News: BIMI Surges Forward With Valimail’s Amplify Solution
Fred Sarkis, CEO of PharmaSmart, added, “We are excited to take this next step in our company journey and to partner with CPS in rolling out our new PS-2000D platform, which incorporates 20 years of experience and innovation, and delivers a fully realized, interoperable health solution for retail pharmacy, providers, and their patients. The influx of capital and expertise allows us the platform to aggressively roll out our technologies across the North America.”
Michael Arblaster, Partner of CPS, said, “We are extremely pleased to be partnering with the founding management group at PharmaSmart. We believe that their clinically validated technologies are an invaluable tool for pharmacies to drive foot traffic and increased engagement. We are additionally excited to showcase their value to international markets, primary care settings and employer worksites to advance population health strategies and deploy data-driven improvements to health outcomes.
Recommended AI News: Qualcomm Appoints Don McGuire As Senior Vice President And Chief Marketing Officer
CPS secured term debt financing for the transaction from FirePower Capital and Nicola Wealth.
Trevor Simpson, Associate Partner at Firepower Capital, said, “We are excited to partner with CPS to support PharmaSmart’s growth plan. PharmaSmart’s market position will be cemented through a new contract with a leading North American pharmacy chain, which positions them well for strong and sustained growth. The commitment from PharmaSmart’s customers throughout the pandemic exemplifies the company’s market good will and sustainable healthcare value proposal. Through our diligence process it is clear PharmaSmart’s products are top-tier and provide real value to their pharmacy clients and consumers by delivering a trustworthy, end-to-end health screening and engagement platform that moves the needle in patient outcomes.”
Jurgen van Vuuren, Senior Director of the Nicola Private Debt Fund, said, “We are delighted to partner with CPS and the team at PharmaSmart to support the company’s next phase of growth. PharmaSmart’s management team has an impressive 20+ year track record of success, and their new generation of health kiosks will help both patients and health professionals drive better long-term health outcomes.”
Recommended AI News: Blues Wireless Announces $22 Million Series a Funding to Meet Demand for Cellular Wireless Solutions
Comments are closed.